114 new drugs will be included in the 2025 national medical insurance drug list.

On December 7th, it was learned from the National Medical Insurance Administration that the National Medical Insurance Drug List and the first edition of the Commercial Insurance Innovative Drug List for 2025 were released in Guangzhou. The National Medical Insurance Drug List for 2025 successfully added 114 new drugs, with 50 of them being first-class innovative drugs, with an overall success rate of 88%, significantly higher than the 76% in 2024. 19 drugs were included in the first edition of the Commercial Insurance Innovative Drug List. The National Medical Insurance Drug List for 2025 includes some drugs that fill the gaps in basic medical insurance coverage, such as drugs for triple-negative breast cancer, pancreatic cancer, lung cancer, and other major diseases; drugs for rare diseases such as Langhans cell histiocytosis and Mediterranean anemia intolerant to chelating agents; drugs for chronic diseases such as diabetes, high cholesterol, and autoimmune diseases. Among the 19 drugs included in the first edition of the Commercial Insurance Innovative Drug List, there are drugs for tumor treatment such as CAR-T, drugs for rare diseases such as neuroblastoma and Gaucher's disease, and drugs for Alzheimer's disease treatment. After this adjustment, the total number of drugs in the National Medical Insurance Drug List has increased to 3,253, including 1,857 Western medicines and 1,396 traditional Chinese medicines. The level of coverage in key areas such as cancer, chronic diseases, mental illnesses, rare diseases, and pediatric medications has been significantly improved. This article is reproduced from "Xinhua News Agency"; edited by GMTEight: Xiao Yi Chen.